恩替卡韦治疗慢性乙型肝炎的临床应用研究

摘要

To evaluate the clinical efficacy of entecavir treatment of chronic hepatitis B.Methods:Data of 70 cases of patients with chronic hepatitis B Hospital from 2011 to 2013 treated in our hospital were collected.All the patients were randomly divided into observation group and control group and each group contained 35 cases.Patients in the observation group received entecavir treatment,while patients in the control group received lamivudine treatment.All the patients received medication for at least 40 weeks before the quantitative polymerase chain reaction method was applied to detect the HBV load of each patient before and after treatment at 10 weeks,20 weeks,30 weeks and 40 weeks.The liver function changes of patients in the two groups were compared before and after treatment,while adverse drug reactions were recorded to monitor drug safety.Results:Patients in both two groups were demonstrated declining HBV-DNA levels after 40 weeks intervention,and in the observation group the levels were decreased more significantly.The difference was statistically significant (P<0.05).Alanine aminotransferase (ALT) normalization rates in the observation group were significantly higher than those in the control group (P<0.05).The incidence of adverse drug events was equal in both two groups and no significant difference was observed (P>0.05).Conclusion:Entecavir treatment of chronic hepatitis B patients can inhibit viral replication and improve liver function.It is worthy of clinical promotion.%目的：探讨恩替卡韦治疗慢性乙型肝炎的临床疗效。方法：选择我院2011~2013年收治的70例慢性乙型肝炎患者的资料，将患者随机分为观察组及对照组，各35例，观察组患者应用恩替卡韦治疗，对照组患者应用拉米夫定治疗，用药时间至少为40周，应用聚合酶链反应定量法检测患者治疗前及治疗后10周、20周、30周、40周病毒量，比较两组患者治疗前、后肝功能指标变化情况，同时记录不良反应情况，监测药物安全性。结果：经过40周干预，两组患者HBV-DNA水平均出现下降，观察组患者下降更为明显，比较差异有统计学意义(P<0.05)；观察组患者谷丙转氨酶(ALT)复常率高于对照组，比较差异有统计学意义(P<0.05)；两组患者不良事件发生率相当，无明显差异，无统计学意义(P>0.05)。结论：恩替卡韦治疗慢性乙型肝炎患者，抑制病毒复制及改善肝脏功能方面均有良好疗效，值得在临床推广。